Integration of targeted therapies in gemcitabine chemotherapy regimens

Clinical Lung Cancer

Volumn 4, Issue 4, 2003, Pages 217-223

  Blumenschein Jr , George R ^a   Herbst, Roy S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Angiogenesis; Endostatin; Farnesyltransferase inhibitors; Gefitinib; Inhibitors; Marimastat; Protein kinase C; Receptor targeted therapies; Trastuzumab; Tyrosine kinase inhibitors

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER VACCINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; ISIS 3521; LONAFARNIB; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MITOMYCIN; NAVELBINE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SU 4516; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANEMIA; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CARDIOTOXICITY; CAUSE OF DEATH; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG SPECIFICITY; DRUG TARGETING; FATIGUE; GENE THERAPY; HUMAN; LETHALITY; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MITOSIS INHIBITION; NAUSEA; NEUTROPENIA; NONHUMAN; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; SURVIVAL RATE; THROMBOCYTOPENIA; UNITED STATES;

EID: 0038207864     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2003.n.001     Document Type: Review

References (69)

1. Cancer Facts and Figures 2002. Altanta, GA: American Cancer Society; 2002.
2. Henderson BE, Ross RK, Pike MC. Toward the primary prevention of cancer. Science 1991; 254:1131-1138.
3. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6:633-641.
4. Ganz PA, Figlin RA, Haskell CM, et al. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference? Cancer 1989; 63:1271-1278.
5. Cartei G, Cartei F, Cantone A, et al. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst 1993; 85:794-800.
6. Johnson D. Treatment strategies for metastatic non-small-cell lung cancer. Clin Lung Cancer 1999; 1:34-41.
7. Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27:145-157.
8. Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92:1074-1080.
9. Anderson H, Cottier B, Nicolson M, et al. Phase III study of gemcitabine (Gemzar) vs. best supportive care (BSC) in advanced non-small-cell lung cancer (NSCLC). Lung Cancer 1997; 18:9 (Abstract #24).
10. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999; 91:66-72.
11. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16:2459-2465.
12. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18:122-130.
13. von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol 2000; 18:1351-1359.
14. Gatzemeier U, von Pawel J, Gottfried M, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18:3390-3399.
15. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12:360-367.
16. Kelly K, Crowley J, Bunn PA, Jr., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210-3218.
17. Schiller JH, Harrington D, Sandler A, et al. A randomized phase III trial of four chemotherapy regimens in advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000; 19:1a (Abstract #2).
18. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20:4285-4291.
19. Van Meerbeeck JP, Smit EF, Lianes P, et al. An EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:308a (Abstract #1228).
20. Rudd R, Gower N, James L, et al. Phase III randomized comparison of gemcitabine and carboplatin (GC) with mitomycin, iforfamide, and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21:(Abstract #1164).
21. Sederholm C. Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group. Semin Oncol 2002; 29:50-54.
22. Fontanini G, Vignati S, Bigini D, et al. Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 1995; 31A:178-183.
23. Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3:515-522.
24. Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 2001; 1:719-732.
25. Meric JB, Faivre S, Monnerat C, et al. [Zd 1839 "Iressa"]. Bull Cancer 2000; 87:873-876.
26. Nemunaitis J, Holmlund JT, Kraynak M, et al. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J Clin Oncol 1999; 17:3586-3595.
27. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001; 8:3-9.
28. Kumar R, Mandal M, Vadlamudi R. New insights into anti-HER-2 receptor monoclonal antibody research. Semin Oncol 2000; 27:84-91.
29. Pegram MD, Lopez A, Konecny G, et al. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000; 27:21-25; discussion 92-100.
30. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
31. Langer C, Adak S, Thor A, et al. Phase II Eastern Cooperative Oncology Group (ECOG) pilot study of paclitaxel (P), carboplatin (C), and trastuzumab (T) in HER-2/neu(+) advanced non-small cell lung cancer (NSCLC): early analysis of E2598. Proc Am Soc Clin Oncol 2001; 20:315a (Abstract #1257).
32. Tran H, Herbst R, Glisson B, et al. Herceptin in combonation with cispltin and gemcitabine in patients (pts) with HER2 overexpressing, untreated, advanced, non-small-cell lung cancer (NSCLC): foma; report of phase II trial. Proc Am Soc Clin Oncol 2002; 21:307a (Abstract #1226).
33. Gatzemeier U, Groth G, Hirsh V, et al. Gemcitabine/cisplatin alone and with trastuzumab (Herceptin) in patients with non-small cell lung cancer overexpressing HER2: results of a randomized phase II study. Proc Am Soc Clin Oncol 2002; 21:297a (Abstract #1185).
34. Fontanini G, Vignati S, Lucchi M, et al. Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer 1997; 75:1295-1301.
35. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1:1311-1318.
36. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19:6550-6565.
37. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19:3234-3243.
38. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18:904-914.
39. Saltz L, Rubin M, Hochester H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20:3a (Abstract #7).
40. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001; 7:1204-1213.
41. Abbruzzese J, Rosenberg A, Xiong Q, et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2001; 20:130a (Abstract #518).
42. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62:5749-5754.
43. Raben D, Helfrich BA, Chan D, et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 2002; 29:37-46.
44. Baselga J, Herbst R, LoRusso P, et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability. Proc Am Soc Clin Oncol 2000; 19:177a (Abstract #686).
45. Kris M, Herbst R, Rischin D, et al. Objective regression non-small cell lung cancer patients treated in phase I trials of oral ZD1839 ('Iressa'), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR), 9th World Conference on Lung Cancer, Tokyo, Japan, September, 2000.
46. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20:2240-2250.
47. Uejima H, Nakagawa K, Jukuoka M, et al. A phase I intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients. Ann Oncol 2000; 11:110 (Abstract #502P).
48. Fukuoka M, Yano S, Giaccone G, et al. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002; 21:298a (Abstract #1188).
49. Kris M, Natale R, Herbst R, et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002; 21:292a (Abstract #1166).
50. Giaccone G, Johnson DH, Manegold C, et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 2). Ann Oncol 2002; 13(suppl 5):2-3 (Abstract #40).
51. Johnson DH, Herbst R, Giaccone G, et al. ZD1839 ('Iressa') in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial. Ann Oncol 2002; 13(suppl 5):127-128 (Abstract #4680).
52. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774 following platinum-based chemotherapy in patients with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:310a (Abstract #1235).
53. Ratain M, George C, Janisch L, et al. Phase I trial of erlotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002; 21:76b (Abstract #2115).
54. Patnik A, Eckhardt S, Meyers M, et al. A phase I pharmacokinetic (PK) study of the farnesyltransferase inhibitor, R115777 in combination with gemcitabine (gem). Proc Am Soc Clin Oncol 2000; 19:2a.
55. Khuri FR, Glisson BS, Meyers ML, et al. A phase I study of farnesyltransferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumors: dose finding, pharmacokinetics, efficacy/safety. Proc Am Soc Clin Oncol 2000; 19:205a (Abstract #799).
56. Khuri FR, Herbst RS, Fossella FV. Emerging therapies in non-small-cell lung cancer. Ann Oncol 2001; 12:739-744.
57. Dean N, McKay R, Miraglia L, et al. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Res 1996; 56:3499-3507.
58. Yuen A, Halsey J, George S, et al. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol 2001; 20:309a (Abstract #1234).
59. Ritch PS, Belt R, George S, et al. Phase I/II trial of ISIS 3521/LY900003, an antisense inhibitor of PKC-alpha with cisplatin and gemcitabine in advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21:309a (Abstract #1233).
60. Pluda JM. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 1997; 24:203-218.
61. DeVore RF, Fehrenbacher RS, Herbst RS, et al. A randomized phase II study comparing rhumab VEGF (recombinanat humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 2000; 19:485a (Abstract #1896).
62. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189:300-308.
63. Pritchard SC, Nicolson MC, Lloret C, et al. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. Oncol Rep 2001; 8:421-424.
64. Kodate M, Kasai T, Hashimoto H, et al. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int 1997; 47:461-469.
65. Grupta E, Huang M, Mao Y, et al. Pharmacokinetic (PK) evaluation of BMS-275291, a matrix metalloproteinase (MMP) inhibitor, in cancer patients. Proc Am Soc Clin Oncol 2001; 20:76a (Abstract #301).
66. Munoz-Mateu M, de'Grafenried L, Eckhardt S, et al. Pharmacokdynamic studies of Col-3, a novel matrix metalloproteinase inhibitor, in patients with advanced cancer. Proc Am Soc Clin Oncol 2001; 20:76a (Abstract #302).
67. Carmichael J, Ledermann JA, Woll PJ, et al. Phase IB study of concurrent administration of marmistat and gemcitabine in non-resectable pancreatic cancer. Proc Am Soc Clin Oncol 1998; 17:232a (Abstract #888).
68. Collier M, Shepherd F, Ahmann FR, et al. A novel approach to studying the efficacy of AG3340, a selective inhibitor of matrix metalloproteinases (MMPs). Proc Am Soc Clin Oncol 1999; 18:482a (Abstract #1861).
69. Bissett D, Bissett D, von Pawel J, et al. Phase III study of the matrix metalloproteinase (MMP) inhibitor prinomastat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21:296a (Abstract #1183).